---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-020793"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2026-06-16T20:06:06+00:00"
generated_at: "2026-06-16T20:08:25.183843+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Puma shareholders reject CEO Auerbach's warrant extension to Oct 2028

## Summary
- All 8 director nominees elected; KPMG ratified as auditor for fiscal 2026.
- Advisory say-on-pay approved: 29.3M for, 7.9M against, 0.7M abstain.
- Warrant amendment defeated: 18.2M for, 19.6M against, 0.09M abstain.
- CEO Auerbach's warrant expires Oct 4, 2026; exercisable at $16 for 2.1M shares.

## SEC filing metadata
- accession: 0001437749-26-020793
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2026-06-16T20:06:06+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774926020793/0001437749-26-020793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774926020793/pbyi20260613_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-020793
- JSON: https://secwatch.observer/filing/0001437749-26-020793.json
- Plain text: https://secwatch.observer/filing/0001437749-26-020793.txt

## Key facts
- Shareholder Votes
  PUMA BIOTECHNOLOGY, INC. shareholders rejected Amendment to warrant terms to extend expiration at the 2026-06-11 meeting.
  - Outcome: failed
  - Meeting: 2026-06-11
  source text: Proposal 4: The Company’s stockholders did not approve an amendment to the terms of the warrant, issued to Alan H. Auerbach, President and Chief Executive Officer of the Company on October 4, 2011, as amended on June 15, 2021, to purchase 2,116,250 shares of the Company’s common stock at $16.00 per share (the “Auerbach Warrant”), to extend the term of the Auerbach Warrant from October 4, 2026 until October 4, 2028. For Against Abstain Broker Non-Votes 18,234,150 19,596,238 85,914 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774926020793/0001437749-26-020793-index.htm
- Shareholder Votes
  PUMA BIOTECHNOLOGY, INC. shareholders approved Ratification of KPMG LLP as independent auditor at the 2026-06-11 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal 2: The Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 42,612,940 1,328,476 39,599 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774926020793/0001437749-26-020793-index.htm
- Shareholder Votes
  PUMA BIOTECHNOLOGY, INC. shareholders approved Election of eight directors at the 2026-06-11 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal 1: The Company’s stockholders elected the eight nominated directors identified below, each to serve and to hold office for a one-year term until the close of the Company’s next annual meeting of stockholders in 2027 and until their successors have been duly elected and qualified or until their earlier resignation or removal. Nominee For Withheld Broker Non-Votes Alan H. Auerbach 37,130,678 785,624 6,064,713 Alessandra Cesano 37,472,173 444,129 6,064,713 Allison Dorval 37,447,432 468,870 6,064,713 Michael P. Miller 37,220,974 695,328 6,064,713 Jay M. Moyes 36,586,798 1,329,504 6,064,713 Adrian M. Senderowicz 37,217,253 699,049 6,064,713 Brian Stuglik 37,372,588 543,714 6,064,713 Troy E. Wilson 32,546,955 5,369,347 6,064,713
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774926020793/0001437749-26-020793-index.htm
- Shareholder Votes
  PUMA BIOTECHNOLOGY, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-11 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal 3: The Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 29,326,673 7,878,580 711,049 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774926020793/0001437749-26-020793-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.